期刊
FUTURE MEDICINAL CHEMISTRY
卷 4, 期 2, 页码 187-204出版社
FUTURE SCI LTD
DOI: 10.4155/FMC.11.179
关键词
-
资金
- NIH [R01DA025612]
The field of cannabinoid (CB) drug research is experiencing a challenge as the CB, antagonist Rimonabant, launched in 2006 as an anorectic/anti-obesity drug, was withdrawn from the European market due to the complications of suicide and depression as side effects. There is interest in developing CB2 drugs without CB, psychotropic side effects for drug-abuse treatment and therapeutic medication. The CB, receptor was discovered predominantly in the brain, whereas the CB2 is mainly expressed in peripheral cells and tissues, and is involved in immune signal transduction. Conversely, the CB2 receptor was recently detected in the CNS, for example, in the microglial cells and the neurons. While the CB2 neurons activity remains controversial, the CB2 receptor is an attractive therapeutic target for neuropathic pain, immune system, cancer and osteoporosis without psychoactivity. This review addresses CB drug abuse and therapeutic potential with a focus on the most recent advances on new CB2 ligands from the literature as well as patents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据